Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

North America and Europe Artificial Pancreas Systems Market – Insights

Artificial pancreas system is a diabetes management system that is designed to continuously monitor glucose levels and manage insulin delivery in case of hyperglycemia and hypoglycemia.

North America and Europe artificial pancreas systems market is estimated to account for US$ 126.8 Mn in terms of value in 2019 and is expected to reach US$ 320.2 Mn by the end of 2027.

North America and Europe Artificial Pancreas Systems Market: Drivers

Increasing incidence of type 1 diabetes is expected to boost growth of North America and Europe artificial pancreas systems market over the forecast period. For instance, according to the Centers for Disease Control and Prevention (CDC), in the U.S., around 40,000 people are diagnosed with Type 1 diabetes, annually, and by 2050, 5 million people are expected to be diagnosed with the disease, in the country.

Moreover, increasing adoption of high-end systems in diabetes management is also expected to aid in growth of the market. This is owing to several drawbacks of conventional systems used for diabetes management such as need to take insulin injections at multiple times and recalibrating the Continuous Glucose Monitoring (CGM) devices. Moreover, conventional systems require user or caregiver interference for insulin delivery.

North America region held dominant position in North America and Europe artificial pancreas systems market in 2018, accounting for 67.4% share in terms of value, followed by Europe.

North America & Europe Artificial Pancreas Systems  | Coherent Market Insights

North America and Europe Artificial Pancreas Systems Market: Restraints

Unfavorable reimbursement policies are expected to hinder growth of North America and Europe artificial pancreas systems market. The U.S. Centers for Medicare and Medicaid Services provides reimbursement only for professional CGM systems such as iPro 2.  Reimbursement is considered an essential aspect in diabetes treatment and management, owing to high cost of these treatments. However, reimbursement for CGM systems by government-aided organizations or private payers is limited. A CGM device is used for monitoring and not for treatment; hence, there is no positive outcome from the use of these devices. Therefore, reimbursement for sensors and other accessories used in CGM devices is not provided by health insurance companies.

Moreover, lack of fully automated dual hormone artificial pancreas system is also expected to hamper growth of the market. This can be attributed to lack of commercially available room-temperature-stable glucagon, device complexity, and the short duration, and small size of clinical studies.

North America and Europe Artificial Pancreas Systems Market: Opportunities

Development of meal detection algorithms can increase the scope and adoption of artificial pancreas system for insulin dosing process. Such algorithm can be integrated with artificial pancreas systems to accurately determine meal size and timing.

Development of hybrid closed loop artificial pancreas systems is also expected to offer lucrative growth opportunities for players in North America and Europe artificial pancreas systems market. For instance, in December 2019, Tandem Diabetes Care, Inc. received the U.S. FDA clearance for its t:slim X2 insulin pump with Control-IQ technology, an advanced hybrid-closed loop feature.

Diabetes type 1 segment in North America and Europe artificial pancreas systems market was valued at US$ 105.7 Mn in 2018 and is expected to reach US$ 314.3 Mn by 2027 at a CAGR of 12.9% during the forecast period.

Market Trends/Key Takeaways

The adoption of quick acting insulin analogues such as aspart, glulisine, and lispro has increased in are employed in artificial pancreas systems as their use helps in mimicking physiological function of insulin release after a meal. The approach also helps to overcome the time lag between actual blood-glucose level and interstitial blood-glucose measurement by CGM.

Major players in the market are focused on offering reliable and advanced sensors in artificial pancreas systems. For instance, Medtronic offers Enlite sensor, a smaller and more reliable sensor compared to its previous glucose sensor i.e. sofsensor.

North America and Europe Artificial Pancreas Systems Market: Competitive Landscape

Major players operating in North America and Europe artificial pancreas systems market include, Medtronic Plc., Johnson and Johnson Services Inc., Dexcom Inc., Insulet Corporation, Tandem Diabetes Care Inc., and Cellnovo.

North America and Europe Artificial Pancreas Systems Market: Competitive Landscape

Key players in the market are focused on adopting partnership and collaboration strategies to expand their product portfolio. For instance, in October 2019, Tandem Diabetes Care Inc. partnered with Abbott to develop and commercialize integrated diabetes solutions that combine Abbott's glucose sensing technology with Tandem's insulin delivery systems.

Key players in the market are also focused on developing rapid insulin for artificial pancreas systems. For instance, in January 2019, Adocia announced the first home-use trial to test its BioChaperone Lispro, a rapid insulin, in Beta Bionics autonomous insulin delivery system, the iLetTM.

An artificial pancreas is a man-made device which replicates the functions of a pancreas. It is capable of releasing insulin in response to the changing levels of blood glucose in the body similar to natural pancreas. Types of artificial pancreas include closed-loop artificial pancreas, bionic pancreas, and implanted artificial pancreas. Companies such as Beta Bionics, Bigfoot Biomedical, Medtronic, Insulet, and others are present in the artificial pancreas market. Moreover, Approvals, launches and frequent partnerships among key players for development of novel artificial pancreas is expected to drive the global artificial pancreas device system (APDS) market growth over the forecast period. For instance, In July 2018, Beta Bionics, Inc., announced the U.S. FDA approval of a supplement filed by Beta Bionics to its previously approved investigational device exemption (IDE), expanding ongoing home-use clinical trials testing its new integrated technology, which combines the iLet bionic pancreas and the Senseonics Eversense CGM. With this approval, Beta Bionics, Inc. began clinical testing of Eversense-compatible iLet comes less than three weeks after Senseonics received the U.S. FDA approval to begin commercial marketing of Eversense for adults with diabetes.

Restraints of the North America & Europe Artificial Pancreas Systems Market

Restraining factors such as high costs, and possibility of inappropriate dosing of insulin are expected to restrain North America & Europe artificial pancreas systems market growth over the forecast period.

Key features of the study:

  • This report provides in-depth analysis of the North America & Europe artificial pancreas systems market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2019–2027), considering 2018, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the North America & Europe artificial pancreas systems market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Medtronic Plc., Johnson and Johnson Services Inc., Dexcom Inc., Insulet Corporation, Tandem Diabetes Care Inc., and Cellnovo
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The North America & Europe artificial pancreas systems market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  •  North America & Europe Artificial Pancreas Systems Market, By Disease Type:
    • Diabetes Type 1
    • Diabetes Type 2
  • North America & Europe Artificial Pancreas Systems Market, By End User:
    • Hospitals
    • Clinics
  • North America & Europe Artificial Pancreas Systems Market, By Region:
    • North America
      • By Disease Type
        • Diabetes Type 1
        • Diabetes Type 2
          • By End User:
            • Hospitals
            • Clinics
          • By Country:
            • U.S.
            • Canada
    • Europe
      • By Disease Type
        • Diabetes Type 1
        • Diabetes Type 2
          • By End User:
            • Hospitals
            • Clinics
          • By Country:
            • U.K.
            • France
            • Germany
            • Spain
            • Italy
            • Russia
            • Rest of Europe
  • Company Profiles
    • Medtronic Plc*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Johnson and Johnson Services Inc.
    • Dexcom Inc.
    • Insulet Corporation
    • Tandem Diabetes Care Inc.
    • Cellnovo

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Disease Type
      • Market Snippet, By End User
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Technological Advancement
    • Regulatory Scenario
  4. North America & Europe Artificial Pancreas Systems Market, By Disease Type, 2017 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2019–2027
      • Segment Trends
    • Diabetes Type 1
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
      • Segment Trends
    • Diabetes Type 2
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
      • Segment Trends
  5. North America & Europe Artificial Pancreas Systems Market, By End User, 2017 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2019–2027
      • Segment Trends
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
    • Clinics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
  6. North America & Europe Artificial Pancreas Systems Market, By Regions, 2017 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2019–2027
      • Segment Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
  7. Competitive Landscape
    • Company Profiles
      • Medtronic Plc
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Johnson and Johnson Services Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Dexcom Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Insulet Corporation
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Tandem Diabetes Care Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Cellnovo
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 13 market data tables and 15 figures on “North America & Europe Artificial Pancreas Systems Market – Global forecast to 2027.

Frequently Asked Questions

The North America & Europe artificial pancreas systems market is expected to reach US$ 320.2 Mn by the end of 2027.
Major players operating in the North America & Europe artificial pancreas systems market include Medtronic Plc., Johnson and Johnson Services Inc., Dexcom Inc., Insulet Corporation, Tandem Diabetes Care Inc., and Cellnovo.
Unfavorable reimbursement policies and lack of fully automated dual hormone artificial pancreas system are some of the major factors that are expected to hamper growth of the market over the forecast period.
Increasing incidence of type 1 diabetes and rising adoption of high-end systems in diabetes management are the major factors that are expected to propel growth of the market over the forecast period.
The North America & Europe artificial pancreas systems market is expected to account for US$ 126.8 Mn in terms of value in 2019.
Among regions, North America held hold a dominant position in the North America & Europe artificial pancreas systems market in 2018, accounting for 67.4% share, in terms of value, followed by Europe.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner